Review Paper Published by CureLab Veterinary and University of Camerino Shows Additional Opportunities for Use of Elenavet in Treating Domestic Animals
CureLab Veterinary is preparing to start the USDA-CVB process with its patented product and is raising funds to complete the USDA-CVB licensing process in the United States
May 12, 2022
May 12, 2022
CureLab Veterinary’s DNA Plasmid, Elenavet, Designated a Biologic Veterinary Product by the European Medicines Agency
CureLab Veterinary plans to obtain regulatory approval in Europe, a market with significant revenue potential
May 6, 2022
May 6, 2022
CureLab Veterinary Secures Patent Protection for P62 Plasmid Therapeutic in South Korea
Patent registration in South Korea enables CureLab Veterinary to pursue a market with high commercial potential
April 23, 2022
April 23, 2022
University of Camerino Signs Strategic Partnership with CureLab Veterinary to Revolutionize Cancer Treatment for Companion Animals
The university is also renewing its agreement with CureLab Oncology to support its phase II clinical trials
